



## **iTeos Therapeutics to Present Data from First- in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020**

April 20, 2020

**Gosselies, Belgium and Cambridge, MA – April 20, 2020.** iTeos Therapeutics, a privately-held biotechnology company developing novel cancer immunotherapies, announces today that it will present initial data on the first-in-human study of its highly innovative and differentiated A<sub>2A</sub> receptor antagonist, EOS-850 in a virtual poster presentation at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2020, taking place April 27-28th.

The abstract and video presentation details are as follows:

**Title:** First in human study with EOS100850, a novel potent A<sub>2A</sub> antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers (CT152)

**Session:** Phase I Clinical Trials

**Abstract #:** 10228

**Authors:** Laurence Buisseret, et al.

The video presentation and full abstract will be available on the [AACR conference website](#) from 9:00 AM ET on Monday, April 27th.

### **For further information, please contact:**

Michel Detheux, CEO

iTeos Therapeutics SA

[info@iteosterapeutics.com](mailto:info@iteosterapeutics.com)

Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji

Consilium Strategic Communications

+44 203 709 5700

[iteos@consilium-comms.com](mailto:iteos@consilium-comms.com)

Sarah McCabe and Zofia Mita

Stern Investor Relations, Inc.

+ 1 212 362 1200

[iTeos@sternir.com](mailto:iTeos@sternir.com)